Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0V5LJ
|
||||
| Former ID |
DIB016512
|
||||
| Drug Name |
JNJ-10329670
|
||||
| Synonyms |
Cathepsin S inhibitors (autoimmune disease); JNJ-10329670; Cathepsin S inhibitors (autoimmune disease), J&J PRD; Cathepsin S inhibitors (autoimmune disease), Johnson & Johnson
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Autoimmune diabetes [ICD10:E08-E13] | Investigative | [543601] | ||
| Company |
Johnson & Johnson Pharmaceutical Research & Development LLC
|
||||
| Formula |
C30H34ClF3N6O3S
|
||||
| Canonical SMILES |
C1CCCN1C(=O)CSc1c(C(F)(F)F)ccc(c1)c1c2CN(CCc2n(CC(CN2CC<br />C(CC2)C)O)n1)C(=O)C
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cathepsin S | Target Info | Inhibitor | [543601] | |
| NetPath Pathway | Leptin Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.